Who are the top 10 players that dominate the cancer drug market? And who's growing fastest?
Severin Schwan, CEO Roche, speaks during a February 2017 press conference in Basel, Switzerland AP Images
The stellar sales performance of new immunotherapy drugs is driving a boom in investment dollars flowing into the field. And it’s not hard to see why. Immunotherapy is delivering more sales, earlier exits, and higher returns on investment for biotech investors.
Last year, immuno-oncology drugs snagged 33% of all dollars spent on cancer drugs. That’s despite the fact that these therapies only make up 9% of all FDA-approved oncology drugs. These numbers underscore a simple fact in biopharma: If you’re a major player in the cancer market, or want to become one, targeting immuno-oncology has become one of the favorite strategies for growing sales — quickly.
In this special report, we decided to give you all an overview of the biggest players in the cancer area, including their successes, what’s top of mind in I/O, and the challenges that lie ahead for the top 10 companies. Includes charts and a table of select late-stage immuno-oncology therapies.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters